Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer: Randomized RTOG trial 0315

Journal of the National Cancer Institute

Volumn 102, Issue 8, 2010, Pages 547-556

  Zachariah, Babu ^a,b   Gwede, Clement K ^b   James, Jennifer ^c   Ajani, Jaffer ^d   Chin, Lisa J ^e   Donath, David ^f   Rosenthal, Seth A ^g   Kane, Brent L ^h   Rotman, Marvin ⁱ   Berk, Lawrence ^b   Kachnic, Lisa A ^j  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c RADIATION THERAPY ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Howard Hughes Medical Institute   (United States)

^f NOTRE DAME HOSPITAL   (Canada)

^g Radiological of Sacramento ^*  (United States)

^h Neurosciences Critical Care Units   (United States)

ⁱ SUNY DOWNSTATE MEDICAL CENTER   (United States)

^j BOSTON UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; OCTREOTIDE; PLACEBO; ANTIDIARRHEAL AGENT;

ACUTE DIARRHEA; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; INTESTINE FUNCTION; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; ACUTE DISEASE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANUS TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG ADMINISTRATION; HEALTH CARE PLANNING; HOSPITALIZATION; INCIDENCE; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; RECTUM TUMOR; TREATMENT FAILURE; UTILIZATION REVIEW;

ACUTE DISEASE; ADULT; AGED; ANTIDIARRHEALS; ANTINEOPLASTIC AGENTS; ANUS NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIARRHEA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTH RESOURCES; HUMANS; INCIDENCE; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; OCTREOTIDE; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RECTAL NEOPLASMS; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 77951626978     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq063     Document Type: Article

References (46)

1. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society; 2009.
2. Steele GD Jr., Herndon JE, Bleday R, et al. Sphincter-sparing treatment for distal rectal adenocarcinoma. Ann Surg Oncol. 1999;6(5):433-441. (Pubitemid 29379560)
3. Horton JK, Tepper JE. Staging of colorectal cancer: past, present, and future. Clin Colorectal Cancer. 2005;4(5):302-312. (Pubitemid 40309376)
4. Wolmark N, Wieand HS, Hyams DM, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000;92(5):388-396. (Pubitemid 30154820)
5. Tepper JE, O'Connell M, Niedzwiecki D, et al. Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control-final report of intergroup 0114. J Clin Oncol. 2002;20(7):1744-1750. (Pubitemid 34273262)
6. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-1740.
7. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997;15(5):2040-2049. (Pubitemid 27209535)
8. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996;14(9):2527-2539. (Pubitemid 26300120)
9. Papillon J. Radiation therapy in the conservative management of cancers of the low rectum and anal canal. Int J Colorectal Dis. 1986;1(4):251-255. (Pubitemid 18002917)
10. Papillon J, Montbarbon JF. Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum. 1987;30(5):324-333. (Pubitemid 17078513)
11. Salmon RJ, Fenton J, Asselain B, et al. Treatment of epidermoid anal canal cancer. Am J Surg. 1984;147(1):43-48. (Pubitemid 14220381)
12. Miller RC, Martenson JA, Sargent DJ, Kahn MJ, Krook JE. Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. Int J Radiat Oncol Biol Phys. 1998;41(3):593-598. (Pubitemid 28275089)
13. Grann A, Minsky BD, Cohen AM, et al. Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer. Dis Colon Rectum. 1997;40(5):515-522. (Pubitemid 27200688)
14. Wong SJ, Winter K, Meropol NJ, et al. RTOG 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer (meeting abstracts). J Clin Oncol. 2008;26(15 suppl):4021.
15. Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914-1921. (Pubitemid 351574921)
16. Dahlberg M, Glimelius B, Graf W, Pahlman L. Preoperative irradiation affects functional results after surgery for rectal cancer: results from a ran-domized study. Dis Colon Rectum. 1998;41(5):543-549; discussion 549-551.
17. Kollmorgen CF, Meagher AP, Wolff BG, Pemberton JH, Martenson JA, Illstrup DM. The long-Term effect of adjuvant postoperative chemoradio-Therapy for rectal carcinoma on bowel function. Ann Surg. 1994;220(5):676-682. (Pubitemid 24355781)
18. Lundby L, Krogh K, Jensen VJ, et al. Long-Term anorectal dysfunction after postoperative radiotherapy for rectal cancer. Dis Colon Rectum. 2005;48(7):1343-1349; discussion 1349-1352; author reply 1352. (Pubitemid 40933860)
19. Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a con-sensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007;14(1):13-20.
20. Wadler S, Benson AB III, Engelking C, et al. Recommended guidelines for the treatment of chemotherapy-induced diarrhea. J Clin Oncol. 1998;16(9):3169-3178. (Pubitemid 28417440)
21. Benson AB III, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926. (Pubitemid 41079912)
22. Johansson C, Efendic S, Wisen O, Uvnas-Wallensten K, Luft R. Effects of short-Time somatostatin infusion on the gastric and intestinal propulsion in humans. Scand J Gastroenterol. 1978;13(4):481-483. (Pubitemid 8354141)
23. Ruskone A, Rene E, Chayvialle JA, et al. Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Dig Dis Sci. 1982;27(5):459-466. (Pubitemid 12161538)
24. Maton PN. The use of the long-Acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterol Clin North Am. 1989;18(4):897-922. (Pubitemid 20077335)
25. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol. 1993;11(1):148-151. (Pubitemid 23059987)
26. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Control of chemotherapy-induced diarrhea with octreotide. A randomized trial with placebo in patients receiving cisplatin. Oncology. 1994;51(1):70-73.
27. Gebbia V, Carreca I, Testa A, et al. Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy. Anticancer Drugs. 1993;4(4):443-445. (Pubitemid 23253701)
28. Rosenoff SH, Gabrail NY, Conklin R, et al. A multicenter, randomized trial of long-Acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol. 2006;4(6):289-294. (Pubitemid 44203632)
29. Nikou GC, Polyzos A, Kostalas G, Avramopoulos H. Octreotide administration and gut hormone levels in patients with chemotherapy-induced diarrhea. Hellenic J Gastroenterol. 1994;7(2):111-114. (Pubitemid 24301659)
30. Rosenoff S. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-Acting formulation in cancer patients: 11 case studies. Support Care Cancer. 2004;12(8):561-570. (Pubitemid 39062547)
31. Rosenoff SH. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy. Eur J Cancer Care (Engl). 2004;13(4):380-383. (Pubitemid 39178302)
32. Mystakidou K, Katsouda E, Tsilika E, et al. Octreotide long-Acting formulation (LAR) in chronic loperamide-refractory diarrhea not related to cancer treatment. Anticancer Res. 2006;26(3B):2325-2328. (Pubitemid 43980195)
33. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27(7-8):365-375.
34. Trotti A, Johnson DJ, Gwede C, et al. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI). Int J Radiat Oncol Biol Phys. 1998;42(2):257-261. (Pubitemid 28502770)
35. Johnson DJ, Casey L, Noriega B. A pilot study of patient quality of life during radiation therapy treatment. Qual Life Res. 1994;3(4):267-272. (Pubitemid 24301634)
36. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56(6):899-905.
37. Wei JT, Dunn RL, Sandler HM, et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol. 2002;20(2):557-566. (Pubitemid 34072540)
38. Pilepich MV, Paulus R. St Clair W, Brasacchio RA, Rostock R, Miller RC. Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapy. Am J Clin Oncol. 2006;29(2):132-137. (Pubitemid 44270950)
39. McMillan SC, Bartkowski-Doda L. Measuring Bowel Elimination.Wilsonville, OR: Jones and Bartlett Inc.; 1997.
40. Cytel Inc. Cytel Statitical Software & Services. East® Version 5. 2007. Cambridge, MA: Cytel Inc.
41. Henderson AR. The bootstrap: a technique for data-driven statistics. Using computer-intensive analysis to explore experimental data. Clin Chim Acta. 2005;359(1-2):1-26. (Pubitemid 41116294)
42. Haddock MG, Sloan JA, Bollinger JW, Soori G, Steen PD, Martenson JA. Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial. J Clin Oncol. 2007;25(10):1255-1259. (Pubitemid 46640572)
43. Martenson JA, Bollinger JW, Sloan JA, et al. Sucralfate in the prevention of treatment-induced diarrhea in patients receiving pelvic radiation therapy: a North Central Cancer Treatment Group phase III double-blind placebo-controlled trial. J Clin Oncol. 2000;18(6):1239-1245. (Pubitemid 30159841)
44. Martenson JA, Halyard MY, Sloan JA, et al. Phase III, double-blind study of depot octreotide versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy: results of North Central Cancer Treatment Group N00CA. J Clin Oncol. 2008;26(32):5248-5253.
45. Yavuz MN, Yavuz AA, Aydin F, Can G, Kavgaci H. The efficacy of octreotide in the therapy of acute radiation-induced diarrhea: a randomized controlled study. Int J Radiat Oncol Biol Phys. 2002;54(1):195-202.
46. Radiation Therapy Oncology Group Trial 0822. A phase II evaluation of preoperative chemoradiotherapy utilizing Intensity Modulated Radiation Therapy (IMRT) in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer.